Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 15 | 2023Wegovy Advertising Paused Due to High Demand; Inventiva Ph2 Lanifibranor T2DM and NAFLD Results; FDA Accepts Gan & Lee’s Bs-Aspart BLAPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other Jun 12 | 2023Novartis to Acquire Chinook; Novo Nordisk Expands Danish FacilityPurchase Blast
$599
Posted in: Insulin Delivery, Other Jun 09 | 2023AstraZeneca Partners for T1DM Cell Therapy; New Lilly Care TrialPurchase Blast
$599
Posted in: Glucose Monitoring Jun 08 | 2023Know Labs Unveils Non-Invasive Glucose Monitor PrototypePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jun 05 | 2023Novo to Acquire Biocorp; Akero Announces Ph2b SYMMETRY Results; Enterin Initiates Ph1a ENT-03 StudyPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Jun 02 | 2023Lilly Initiates Ph3 Retatrutide Obesity Program; UnitedHealthcare Expands Coverage to Eversense E3 CGMPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jun 02 | 2023Updated FDA Draft Guidance for Diabetes Trials; Esperion Files CLEAR Outcomes sNDAs; Positive Glyscend Topline Ph2a GLY-200 Results and ADA 2023 Presentations; Pharming Sells PRV to NovartisPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring May 31 | 2023Akebia Rejected Again by FDA; Know Labs Announces Positive Bio-RFID Results; Lilly and XtalPi Collaborate for AI Drug Discovery; Structure Doses First Patient in Ph2a Oral GLP-1RA StudyPurchase Blast
$599
Posted in: GLP-1RA, Other May 24 | 2023Novo Partners with Life Edit Therapeutics; Biocon FY Q4 '23 Earnings; Lilly initiates second trial in orforglipron obesity pivotal program; Mannkind appoints Burkhard Blank as EVP of R&D and CMOPurchase Blast
$599
Posted in: GLP-1RA May 22 | 2023Novo OASIS 1 Topline Results; Intercept Hosts Post-adcom Update; Lilly Initiates Oral Obesity GLP-1RA Program; May CHMP AgendaPurchase Blast
$599
Posted in: Insulin Delivery May 19 | 2023FDA Clears Beta Bionics iLet ACE Pump and iLet Dosing Decision SoftwarePurchase Blast
$599
Posted in: SGLT2i May 18 | 2023US Supreme Court Rules in Favor of Regeneron/Sanofi Praluent LitigationPurchase Blast
$599
Posted in: Other May 17 | 2023Intercept Faces Uphill Battle for Impending FDA Adcom; Briefing Documents ReleasedPurchase Blast
$599
Posted in: Other May 16 | 2023Viking Topline Ph2b VK2809 NASH Data; Chinook and Ionis Partner to Develop ASO Therapy for CKDPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, SGLT2i May 12 | 2023Structure Therapeutics Advances Oral GLP-1RA to Ph2; Embecta and Tidepool Partner for T2DM Patch Pump AID Development; New SOLOIST-WHF AnalysisPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other May 11 | 2023Senate Targets PBMs and Insulin Manufacturers; Zealand and Dario Q1 ’23 Earnings; Cytokinetics Initiates Ph1 Trial for Potential HFpEF TherapyPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Insulin Delivery, Other May 10 | 2023BI and Zealand Announce Positive Ph2 BI 456906 Obesity Results; Senseonics and MannKind Q1 ’23 Earnings; Sanofi Study Demonstrates Benefit of Dario; MyFitnessPal and Google Health CGM Integration; Diamyd’s Remygen Fails To Support Durable Treatment EffectPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
